Prognosis of Anaplastic Thyroid Cancer with Distant Metastasis

Area of Science:

• Oncology
• Endocrinology
• Medical Statistics

Background:

• Anaplastic thyroid cancer (ATC) is an aggressive malignancy with a high mortality rate, originating from follicular thyroid cells.
• Characterizing ATC is challenging due to the rarity of cases with distant metastasis.
• Understanding the clinical features of metastatic ATC is crucial for improving patient outcomes.

Purpose of the Study:

• To determine the clinical characteristics of anaplastic thyroid cancer (ATC) with distant metastasis.
• To evaluate the overall survival rates for patients with ATC, including those with distant and brain metastasis.

Main Methods:

• Retrospective review of medical records for 152 patients diagnosed with ATC between January 2004 and March 2022.
• Analysis of primary endpoints including overall survival for the total patient cohort, patients with distant metastasis, and patients with brain metastasis.
• Comparison of survival rates and median survival times between groups.

Main Results:

• A significant proportion (88/152) of ATC patients presented with distant metastasis at diagnosis.
• The 5-year disease-specific survival was substantially lower for ATC with distant metastasis (10%) compared to overall ATC (24%).
• Median survival was significantly shorter for patients with distant metastasis (171 days) versus the total ATC group (228.5 days).
• Brain metastasis occurred in 11% of ATC cases, suggesting the utility of brain imaging at diagnosis and during follow-up.

Conclusions:

• Anaplastic thyroid cancer with distant metastasis is associated with significantly poorer survival outcomes.
• The high incidence of distant metastasis at diagnosis underscores the aggressive nature of ATC.
• Consideration of brain imaging (MRI or CT) is recommended for diagnosis and follow-up in ATC patients due to the prevalence of brain metastasis.